Prophylactic inhaled zanamivir (Relenza; GlaxoSmithKline) prevents the spread of influenza types A and B within families even when the index case is not treated.
That’s according to the results of a double blind, randomized, placebo-controlled trial involving 487 households. Lead investigator Dr. Arnold S. Monto of the University of Michigan in Ann Arbor told Reuters Health: “The take-home message is that neuraminidase inhibitors are effective in prophylaxis and therapy.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!